Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Howmet Aerospace Inc (HWM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Howmet Aerospace IncTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Howmet Aerospace Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Howmet Aerospace Inc trades at $276.48 (market cap $108.82B), while Regeneron Pharmaceuticals Inc trades at $675.45 (market cap $70.47B). The key difference: Howmet Aerospace Inc is the larger of the two by market cap, and Regeneron Pharmaceuticals Inc pays the higher dividend (0.56%). Which is the better fit depends on your goals.

HWMREGN
Market Cap
$108.82B$70.47B
Sector
IndustrialsHealth
52-Week High
$283.23$812.27
52-Week Low
$171.00$545.46
Enterprise Value
$111.07B$64.42B
Dividend Yield
0.18%0.56%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Howmet Aerospace Inc

Howmet Aerospace (HWM) trades at $271.98, down 0.17% on the day, with a neutral technical signal and bullish moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.22 exceeding the $1.11 estimate. Financials show robust profitability, including a 20.22% net income margin and 33.98% ROE, though valuation ratios like a P/E of 63.21 appear elevated. Recent news highlights commercial aerospace demand driving growth, with shares gaining 249% since May 2024 according to FXEmpire on July 15, 2026.

The outlook remains positive due to sustained aerospace demand and analyst consensus favoring buys, but risks include high valuation sensitivity and market volatility. Upside to the $317.63 price target offers potential, yet investors should weigh premium multiples against earnings growth momentum and sector cyclicality.

Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals (REGN) trades at $671.9, down 0.71% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and consistent earnings beats in recent quarters. Analyst consensus is strongly bullish with a $764.50 price target, though recent news highlights a securities class action lawsuit filed in July 2026.

Outlook remains positive due to solid financials and analyst support, but risks include legal uncertainties from ongoing litigation and potential market volatility. The stock offers value with a P/E of 16.52, trading below the consensus target, presenting upside if legal concerns resolve favorably.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Howmet Aerospace Inc

Howmet Aerospace provides advanced engineered solutions for the aerospace and transportation industries. It specializes in jet engine components, aerospace fastening systems, and forged aluminum wheels.

Read more on HWM

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN